A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT05957367 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

GIST

Interventions

DRUG: Inlexisertib
DRUG: Ripretinib

Sponsor

Deciphera Pharmaceuticals, LLC